Mucositis Clinical Trial
Official title:
The Effects of Whole Food Intervention on Mucositis in Patients Being Treated for Head and Neck Cancer With Radiation With or Without Chemotherapy
This is a study to see if a Whole Food Intervention (WFI) consisting of yogurt, butter, honey, vanilla, and glutamine will lower the frequency or severity of mucositis in head and neck cancer patients undergoing standard treatment.
The proposal is a one center, open label, randomized pilot study to evaluate the safety,
tolerability and compliance of a Whole Food Intervention with Standard of Care for patients
with head & neck cancer. The primary objectives are:
1. To determine whether patients will use a Whole Food Intervention 4-6 times daily, and
2. To determine whether the Whole Food Intervention will reduce the incidence of grade 2
or greater mucositis from 75% historically seen to 25% .
3. To determine whether Whole Food Intervention will reduce the incidence of treatment
breaks from >19% to < 10% (see section 9 for comments)
This Whole Food Intervention will be taken by mouth before the start of radiation therapy,
with or without chemotherapy and for the entire treatment therapy.
Mucositis-related pain and reduction of oral intake will be quantified by using validated
assessment tools. Weight loss or gain, diarrhea, constipation or no change in bowel function
and the use of conventional medication for radiation-induced mucositis will be recorded.
Chart review and patient questionnaires will be used to establish whether a treatment break
or dose reduction for radiation of chemotherapy was required due to radiation
mucositis-related symptoms. Complete Chemistry Profile and Complete Blood Count will be
extracted from the patients' medical oncologist's or radiation oncologist's records. The
patient will continue to use standard mucositis therapies if desired as prescribed by the
treating oncology physician.
The Whole Food Intervention consists of yogurt, butter, honey, vanilla, and glutamine with 3
portioning cups, equal to approximately 12 ounces, taken daily before starting radiation
therapy. A questionnaire will be used to record symptoms and doses taken. The patient will
continue to use standard mucositis therapies as prescribed by the treating oncology
physician.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252926 -
Local Anesthetic Treatment of Oral Pain in Patients With Mucositis
|
Phase 2 | |
Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
Completed |
NCT00357942 -
Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy
|
Phase 4 | |
Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
Completed |
NCT02605382 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis
|
Phase 2 | |
Completed |
NCT02639377 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis
|
Phase 2 | |
Completed |
NCT00956254 -
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
|
Phase 3 | |
Completed |
NCT00584597 -
A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis
|
Phase 1 | |
Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
Completed |
NCT05181943 -
Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT03713567 -
Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis
|
N/A | |
Completed |
NCT02671812 -
Outcome After Dental Implant Treatment
|
||
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT01707641 -
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
|
Phase 4 | |
Completed |
NCT01015183 -
Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
|
Phase 2/Phase 3 | |
Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 |